Abstract | OBJECTIVE: DESIGN: Prospective, observational, noncomparative, open-label. METHODS: A total of 6082 patients of both genders, aged ≥40 years, received a single daily oral dose of quinapril 40mg for a period of 8 weeks. The primary end-point parameter of efficacy was the percentage of patients with adequate control of blood pressure, which was defined as systolic blood pressure (SBP) ≤140mm Hg and diastolic blood pressure (DBP) ≤90mm Hg. For the diabetic group the definition was 130/85mm Hg. Tolerability and safety of antihypertensive drugs was assessed by physical examination and detection of adverse effects potentially related to antihypertensive medication. RESULTS: At the end of the 8-week treatment period with quinapril, adequate control of DBP, SBP and both was found in 90, 56 and 54% of patients, respectively, with a mean difference of 25mm Hg for SBP and of 15mm Hg for DBP as compared with baseline. In hypertensive patients with diabetes mellitus (n = 1269) and in patients previously treated with other ACE inhibitors (n = 2083), quinapril therapy was also associated with statistically significant decreases in mean DBP and SBP (p < 0.0001). A total of 42 adverse events were recorded. No patient failed to complete the study because of adverse events. CONCLUSIONS:
Quinapril 40mg significantly lowered blood pressure, achieving adequate control of DBP in up to 90% of patients with moderate essential hypertension previously unsuccessfully controlled.
|
Authors | C Pueyo, C Diaz, J M Sol, X Masramon, G Hernández, EUREKA Study Group |
Journal | Clinical drug investigation
(Clin Drug Investig)
Vol. 20
Issue 2
Pg. 81-8
( 2000)
ISSN: 1173-2563 [Print] New Zealand |
PMID | 23315349
(Publication Type: Journal Article)
|